geneTherapy

Sangamo Therapeutics Faces Deplorable Stock Plunge Following Pfizer's Withdrawal from Hemophilia Treatment Deal

16 days ago

Sangamo Therapeutics, a company specializing in gene therapy and related innovations, witnessed a catastrophic decline in its stock value after pharmaceutical giant Pfizer decided to terminate their partnership regarding a hemophilia treatment. This abrupt end to the collaboration has sent shockwaves through the markets and raised numerous questions about the future capabilities and financial health of Sangamo.

Breakthrough in Spinal Muscle Atrophy Treatment: Novartis Unveils Promising Results

16 days ago

Novartis has announced encouraging results from a recent clinical study showcasing the effectiveness of a new drug designed to treat spinal muscular atrophy (SMA) in children. This condition affects the motor neurons in the spinal cord, leading to worsening weakness and muscle atrophy, creating substantial challenges for those who suffer from it. The report details how the innovative treatment could potentially alter the lives of young patients battling this debilitating disease.

Roche's Bold $1 Billion Investment to Make Gene Therapies Affordable

3 months ago

In a groundbreaking move within the biotechnology sector, Roche has announced a remarkable investment of $1 billion aimed at making gene therapies more accessible and affordable. This high-stakes initiative comes in response to the widespread concern regarding the exorbitant costs associated with gene treatments, which have often barred patients from receiving potentially life-saving therapies.